Adverse drug reaction-related admissions in paediatrics, a prospective single-centre study by Posthumus, A.G. (Anke) et al.
Adverse drug reaction-related
admissions in paediatrics, a prospective
single-centre study
Anke A G Posthumus,1,6 Carien C W Alingh,1,6 Christian C M Zwaan,2
Kees K van Grootheest,3,4 Lidwien L M Hanff,2 Bregje B C M Witjes,5
Geert W ‘t Jong,2 Matthijs de Hoog2
To cite: Posthumus AAG,
Alingh CCW, Zwaan CCM,
et al. Adverse drug reaction-
related admissions in
paediatrics, a prospective
single-centre study. BMJ
Open 2012;2:e000934.
doi:10.1136/bmjopen-2012-
000934
▸ Prepublication history and
additional material for this
paper are available online. To
view these files please visit
the journal online (http://dx.
doi.org/10.1136/bmjopen-
2012-000934).
Received 29 March 2012
Accepted 20 July 2012
This final article is available
for use under the terms of the
Creative Commons Attribution
Non-Commercial 2.0 Licence;
see http://bmjopen.bmj.com
1Erasmus MC, Rotterdam,
The Netherlands
2Erasmus MC-Sophia
Children’s Hospital,
Rotterdam, The Netherlands
3The Netherlands
Pharmacovigilance Centre
Lareb, Den Bosch,
The Netherlands
4Department of Pharmacy
Section Pharmacotherapy and
Pharmaceutical Care,
University of Groningen,
The Netherlands
5VU University Medical
Center, Amsterdam,
The Netherlands
6AP and CA contributed
equally to the publication
Correspondence to
Dr Matthijs M de Hoog;
m.dehoog@erasmusmc.nl
ABSTRACT
Objective: To investigate the incidence and
characteristics of hospital admissions related to
adverse drug events in the paediatric setting.
Design: Prospective single-centre study.
Setting: A secondary and tertiary paediatric care
centre.
Participants: A total of 683 acutely admitted patients,
aged 0–18 year. All acutely admitted patients, using
medication before admission, were prospectively
screened for possible Adverse Drug Reactions
(ADR)-related admission with a trigger list. Included
cases were analysed with the Naranjo score for the
assessment of causality.
Main outcome measures: This research explored
the incidence of ADR-related admissions and
investigated the relation between ADR and the licensing
status of the medicines, as well as the severity and
potential to prevent the ADRs.
Results: A total of 683 patients were admitted acutely
during the study period, 47 of them were exposed to
cancer chemotherapy. Fifteen patients not exposed to
chemotherapy (2.4%) were admitted due to an ADR.
Five of these 15 ADRs (33%) were caused by
unlicensed or off-label used drugs. Thirty-two patients
exposed to chemotherapy (68.1%) were admitted due
to an ADR; 27 of these (84%) were caused by
unlicensed or off-label used drugs.
Conclusions: In conclusion, this study shows that
ADR-related hospital admissions occur more frequently
in the paediatric population compared with adults, and
more frequently in patients exposed to cancer
chemotherapy. No relation was found between the
unlicensed and off-label used drugs and the incidence
of ADRs.
INTRODUCTION
Adverse Drug Events (ADEs) describe any
untoward medical occurrence that may
present during treatment with a pharmaceut-
ical product but that does not necessarily
have a causal relationship with this treatment.
Adverse Drug Reactions (ADRs) form a part
of ADEs.1 ADRs are deﬁned as an unin-
tended noxious response to a drug.2 The
deﬁnition of a medication error is any pre-
ventable event that may cause or lead to
inappropriate medication use, or patient
harm while the medication is in control of a
healthcare professional, patient or con-
sumer.2 In the context of this study only the
medication errors resulting in ADRs are
taken into account.
Occurrence of ADRs is inherent to the use
of medicines, and in some cases the severity
of an event leads to hospital admission.
ARTICLE SUMMARY
Article focus
▪ The aim of this research was to investigate the
incidence and characteristics of hospital admis-
sions related to adverse drug events in the paedi-
atric setting.
Key messages
▪ Adverse Drug Reactions (ADR)-related hospital
admissions occur more frequently in the paediat-
ric population compared with adults.
▪ ADR-related hospital admissions occur more fre-
quently in paediatric patients exposed to cancer
chemotherapy.
▪ No relation was found between unlicensed and
off-label use of drugs and the incidence of
ADRs.
Strengths and limitations of the study
▪ A prospective study design was used.
▪ To our knowledge our study is the first on hos-
pital admissions related to adverse drug events
in the paediatric setting to be conducted in the
Dutch setting.
▪ The number of patients included in this study
was limited.
▪ The trigger list might have been incomplete.
▪ Data collection depended on information avail-
able in patient records.
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However, most studies on hospital admissions related to
medication use focus on adult patients.3 In adults
ADE-related admissions form a great medical and eco-
nomic burden, with a reported frequency in Dutch hospi-
tals from 1.83% of all acute admissions including
paediatric patients to 5.6% of all acute admitted adults.4 5
The burden in children seems to be lower, amounting up
to 2.09%.6 Yet certain subgroups are at a greater risk, for
example, in children exposed to cancer chemotherapy.
Incidences of up to 22% have been reported.7
Risk factors for ADRs in children are relatively
unknown. Pharmacodynamics and pharmacokinetics in
children differ from adults and therefore the spectrum
of adverse reactions in children may differ as well.8
Furthermore, children are more often exposed to
unlicensed and off-label medication use, which potentially
forms a greater risk for ADRs.9 10 Because part of these
events may be preventable, more knowledge on occurrence
and content of ADRs in the paediatric setting is necessary.
The aim of this study was to prospectively investigate
the incidence of ADRs as well as associated risk factors,
such as licensing state, altered Pharmacokinetics and
Pharmacodynamics (PK/PD)-behaviour or exposure to
cancer chemotherapy in paediatric patients. Furthermore,
severity of events as well as preventability was studied.
METHODS
This prospective study was performed in the Sophia
Children’s Hospital (SCH) in Rotterdam (the
Netherlands) between March and July 2008. The SCH is a
tertiary paediatric teaching hospital and is a major referral
centre for paediatric patients within the South-western
part of the Netherlands (about 4 million inhabitants).
Patients
All patients triaged at the emergency department and
outpatient clinic of the SCH were considered for inclu-
sion if they were acutely admitted to any of the clinical
units of the SCH, or to paediatric wards of surrounding
general hospitals, upon referral from the SCH.
Design
In order to determine the possibility of an ADR-related
admission, all acutely admitted patients were assessed for
the use of medication before admission. Patients admit-
ted due to alcohol or drug abuse, a suicide attempt or
admissions planned more than 24 h in advance were
excluded from the study. Patients using medication were
screened for a possible drug-related admission, based on
a previously published trigger list.5 This trigger list was
adapted for the paediatric setting by the use of an
expert panel consisting of two paediatricians and three
clinical pharmacists. Patients with a positive screening
were included and analysed.
Included cases were assessed independently by a
paediatrician and a pharmacist. Consensus was reached
in a subsequent meeting. The likelihood of an ADR was
determined using the Naranjo score.11 All patients with
a Naranjo score of ≥1 (Naranjo score ‘possible’, ‘likely’
and ‘certainly’) were deﬁned as cases and the licensing
state of the drugs they used were identiﬁed. Medication
registered for children at the Dutch Medicine
Evaluation Board is called ‘licensed’ and medication
that has not been registered for use in children is called
‘unlicensed’. ‘Off-label used medication’ refers to drugs
that are used outside the terms of the product license.12
Furthermore, the degree of severity was scored prospect-
ively based on the Le algorithm and the preventability
was scored based on the Schumock algorithm.13 14
Data were abstracted from patient records and included:
date of birth, gender, reason for admission, number of
admissions before current admission, comorbidity, medica-
tion used before admission (route of administration,
form, dose, frequency and indication for use) and labora-
tory results during admission. When there was uncertainty
about the information in the medical record extra-
information for clariﬁcation was obtained from care provi-
ders involved.
Data from patients exposed to cancer chemotherapy
were analysed separately, because these patients are
expected to have a higher incidence of ADRs than the
general paediatric population.
Analysis
Descriptive statistical methods were used for all end
points.
RESULTS
A total number of 683 patients were admitted acutely to
the SCH during the 18-week research period. In total,
264 patients were admitted for a symptom or sign corre-
sponding with a symptom on the trigger-list and used
medication before admission. Six patients admitted to
the paediatric wards and intensive care unit (ICU) were
excluded because of an autointoxication. The remaining
258 patients on the paediatric wards (211 patients) and
ICU (47 patients) were included in the study. Forty-
seven of these patients were exposed to cancer chemo-
therapy, and all were admitted to the medium care
oncology department. Table 1 lists basic information on
the acute admissions to the SCH and the patients
included in this study.
Common infections, dyspnoea and convulsions were
the most frequent reasons for admission to the paediat-
ric wards and ICU. In the study population the most fre-
quently used types of drugs before admission were,
according to the Anatomical Therapeutical Chemical
(ATC)/DDD index, classiﬁed as drugs for the alimentary
tract and metabolism, the nervous system and anti-
infectives for systemic use.15
For patients exposed to cancer chemotherapy the
most frequent reason for admission was neutropenic
fever. Besides antineoplastic and immunomodulating
agents, most commonly used medicines for these
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patients were drugs for the alimentary tract and metab-
olism and anti-infectives for systemic use.15
For 47 of all patients admitted to the SCH the reason
for admission was an ADR (6.9%), 32 of these patients
were exposed to cancer chemotherapy. For children
admitted with a positive trigger score who used medica-
tion before admission, ADRs were the reason for admis-
sion in 18.2%.
ADRs in patients not exposed to cancer chemotherapy
From all patients who were not exposed to cancer
chemotherapy, 15 were admitted due to an ADR (2.4%)
(table 2). The ADRs in these patients were most com-
monly caused by vaccinations, anti-infectives for systemic
use, immunomodulating agents and drugs for the
nervous system.15 Patients with an ADR used an average
of 4.7 drugs (95% CI 3.72 to 5.84), compared to 4.1
(95% CI 3.84 to 4.38) in children with a positive screen-
ing for the trigger list but without an ADR.
Two ADRs were medication errors, one caused by
licensed drugs and one due to unlicensed used drugs.
One case was a newborn, who was administrated a
10-time higher doses of trimethoprim, the other case
was excessive doses of valproic acid prescribed to a child
with renal failure.
Table 2 Adverse drug reactions in patients not exposed to cancer chemotherapy
ATC* Drug Age† Adverse drug event
Naranjo
score‡ Avoidable?
Licensing
state
A Ranitidine Newborn Urticaria 6 No Licensed
J Amoxicilline Baby/toddler Vomiting 6 No Licensed
J DKTP/HIB vaccine Baby/toddler Dyspnoea 5 No Licensed
J DKTP/HIB vaccine Baby/toddler Fever, vomiting 6 No Licensed
J DKTP/HIB vaccine Baby/toddler Fever 6 No Licensed
J DKTP/HIB vaccine Baby/toddler Fever, refusal of food No
Pneumococcal vaccine 4 Licensed
J DKTP/HIB vaccine Baby/toddler Fever No
Pneumococcal vaccine 4 Licensed
J Tobramycin Child Haemorrhage 9 No Unlicensed
J Tobramycin Child Haemorrhage 10 No Unlicensed
J Trimethoprim Newborn Vomiting 6 Yes Unlicensed
L Infliximab Child Fever, tachycardia,
abdominal pain
6 No Licensed
L Tacrolimus Child Vomiting 4 No Licensed
L Thymocytenglobuline Child Serum sickness 6 No Unlicensed
N Lithium (transmission through
placenta)
Newborn Syncope 6 No Unlicensed
N Valproic acid Child Drowsiness 8 Yes Licensed
*Anatomical Therapeutical Chemical (ATC) classification system of the WHO. A, alimentary tract and metabolism; C, cardiovascular system;
J, anti-infectives for systemic use; L, antineoplastic and immunomodulating agents N, nervous system.15
†Patient age by means of EMeA criteria: preterm, newborn (0–1 month), baby/toddler (1 month–2 years), child (2–11 years) and adolescent
(12–18 years).
‡Probability measured by Naranjo score: ≤0 Adverse Drug Reactions (ADR) doubtful, 1–4 ADR possible, 5–8 ADR likely, ≥9 ADR certain.11
DKTP, Difteria Pertussis Tetanus Polio vaccin; EMeA, European Medicines (Evaluation) Agency; HIB, Haemophylus Influenza B vaccin.
Table 1 Acute admissions to the Sophia Children’s
Hospital
Number of
admissions
Patients
included in
the study
Acute admissions
Total number of
patients admitted
683 258
Patients admitted to
the MCU
437 181
Patients admitted to
the PICU
176 46
Patients admitted to
the NICU
4 0
Patients admitted to
other hospitals
66 31
Gender
Male (%) 403 (59%) 146 (56.6%)
Female (%) 280 (41%) 112 (43.4%)
Age
Median 3 years and
2 months
3 years and
6 months
Range 1 day—17 years
and 11 months
13 days—
17 years and
11 months
MCU, medium care unit; NICU, neonatal intensive care unit;
PICU, paediatric intensive care unit.
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Ten ADRs were caused by licensed prescribed drugs
(67.7%) and ﬁve by unlicensed used drugs (33.3%). All
cases were clinically mild. None resulted in permanent
harm to the patient, signiﬁcant haemodynamic instability
or (in)directly to patient death.13 Both medication errors
were avoidable, all other ADRs were not avoidable.
Patients exposed to cancer chemotherapy
From all 47 patients exposed to cancer chemotherapy,
32 were admitted due to an ADR (68.1%) (table 3). All
ADR-related admissions were caused by chemotherapeu-
tics (ATC code: anti-neoplastic and immunomodulating
agents).15 Twenty-one patients (65.6%) were admitted
for chemotherapy-induced neutropenic fever, of which
17 scored ≥9 for the Naranjo score. The licensing state
of the prescribed drugs inducing neutropenic fever was
determined as well. Two of these ADRs were caused by
licensed prescribed drugs, two by unlicensed used medi-
cation and ﬁve by off-label used drugs. The other 12
neutropenic fever ADRs were caused by a combination
of licensed, off-label and unlicensed used drugs. Table 3
lists the non-neutropenic fever ADRs found in patients
exposed to cancer chemotherapy.
Of all ADRs in patients exposed to cancer chemother-
apy, 5 were caused by licensed prescribed drugs (15.6%),
3 by unlicensed used drugs (9.4%), 8 by off-label used
medication (25%) and 16 by combination of licensed,
unlicensed and off-label used drugs (50%).
All ADRs in patients exposed to cancer chemotherapy
were clinically mild, none of these resulted in perman-
ent harm to the patient, signiﬁcant haemodynamic
instability or (in)directly to patient death.13 None of the
ADR-related admissions in patients exposed to cancer
chemotherapy were avoidable.
DISCUSSION
Overall, in this study, ADR-related hospital admission
occurred in 6.9% of all acutely admitted paediatric
patients, 2.4% in patients non-exposed and 68.1% in
patients exposed to cancer chemotherapy. A study on
ADR-related hospital admissions among adults in the
Netherlands, including patients exposed to cancer
chemotherapy, found a lower percentage of 5.6.5 In
adults polypharmacy (the chronic use of ﬁve or more
oral drugs) was one of the risk factors for an admission
caused by an ADR.5 In children we could not demon-
strate the same relation, although in our study patients
with an ADR used an average of 4.7 drugs. The most
common prescribed types of drugs causing ADEs in the
adult population were platelet aggregation inhibitors,
NSAID’s and anticoagulants.5 In our study population
we found no ADRs caused by these drugs, probably
because antiplatelets and anticoagulants are rarely pre-
scribed to the children. In contrast, vaccinations form a
major cause of ADRs in our study population, whereas
they are rarely prescribed to adult patients.
Table 3 Adverse drug events reactions in patients exposed to cancer chemotherapy, excluding neutropenic fever
ATC* Drug Age† Adverse drug event Naranjo score‡ Avoidable? Licensing state
L Methotrexate Adolescent Pancreatitis 4 No Off-label
L Vincristine Adolescent Constipation 7 No Licensed
L Vincristine Child Ataxia and diarrhoea 9 No Licensed
L Vincristine Child Ataxia and diarrhoea 10 No Licensed
L Asparagines 7 No Licensed
L Doxorubicin 7 No Off-label
L Vincristine Adolescent Retinal haemorrhage 7 No Licensed
L Carboplatin 9 No Unlicensed
L Etoposide Child Vomiting 9 No Unlicensed
L Cisplatin 9 No Unlicensed
L Dexrazoxaan 9 No Off-label
L Doxorubicin Child Anaemia 9 No Unlicensed
L Cytarabine Trombopaenia, petechiea 9 No Off-label
L Mitoxantrone Adolescent 9 No Unlicensed
L Cytarabine Trombopaenia, petechiea 10 No Off-label
L Mitoxantrone Adolescent 10 No Unlicensed
L Methotrexaat 10 No Off-label
L Mercaptopurine 10 No Off-label
L Vincristine Child Leucopaenia 10 No Off-label
L Vincristine Baby/toddler Constipation 6 No Off-label
*Anatomical Therapeutical Chemical (ATC) classification system of the WHO. A, alimentary tract and metabolism; C, cardiovascular system;
J, anti-infectives for systemic use; L, antineoplastic and immunomodulating agents; N, nervous system.15
†Patient age by means of EMeA criteria: preterm, newborn (0–1 month), baby/toddler (1 month–2 years), child (2–11 years), adolescent
(12–18 years).
‡Probability measured by Naranjo score: ≤0 Adverse Drug Reactions (ADR) doubtful, 1–4 ADR possible, 5–8 ADR likely, ≥9 ADR certain.11
EMeA, European Medicines (Evaluation) Agency.
4 Posthumus AAG, Alingh CCW, Zwaan CCM, et al. BMJ Open 2012;2:e000934. doi:10.1136/bmjopen-2012-000934
Adverse drug reaction-related admissions in paediatrics
4300.7802.430. Protected by copyright.
 o
n
 Septem
ber 19, 2019 at Erasm
us M
edical / X51
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2012-000934 on 24 August 2012. Downloaded from 
In our study, we also found that exposure to cancer
chemotherapy is an important risk factor for the occur-
rence of ADRs. This result is also reported by Mitchell
et al,7 who found 22% ADRs in paediatric oncology
patients, compared to 2% in non-oncology patients. The
high incidence of ADRs in patients exposed to cancer
chemotherapy compared to non-exposed paediatric
patients can be explained by the associated neutro-
penia.16 Neutropenic patients have an increased risk of
infections.7 The fact that the percentage reported by
Mitchell et al is much lower than the percentage found in
our study is possibly attributable to the differences
between the two studies. Mitchell et al included patients
with both ‘direct and referred admissions’, whereas our
study focused only on acutely admitted patients. Also the
number of oncology patients included in our study was
much smaller than in the study of Mitchell et al, being 47
in the ﬁrst and 725 in the latter.
In our study all oncology cases were ADRs caused by
antineoplastic and immunomodulating agents, no medi-
cation errors were found. None of the ADR-related
admissions were due to drugs for supportive care.
Mitchell et al describes that 94% of ADRs in these
patients were caused by cancer chemotherapy, which is
comparable to our results.7
The severity of ADRs in patients exposed to cancer
chemotherapy was comparable with the severity of non-
exposed patients. All ADRs were severe because of the hos-
pital admission, but they were clinically mild, not resulting
in permanent harm to the patient, signiﬁcant hemo-
dynamic instability or (in)directly to patient death.13
For patients not exposed to cancer chemotherapy com-
parable percentages of ADR-related admissions (0.59–
4.1%) were found in other paediatric studies.7 17–20
Mitchell et al7 analysed 6546 admissions and found that
2% were caused by ADRs. The majority of these patients
were 0–5 years of age.7 Another study conducted in Spain
showed an incidence of 4.3% for patients in the same-age
categories.18 McKenzie et al19 found an incidence of 2%,
of which 37.8% were ADRs caused by chemotherapeutics.
A meta-analysis on prospective studies found a weighted
average of ADR-related admissions of 2.09%.6 Authors
used different scoring systems for ADRs, none of the
authors of the prospective studies used the Naranjo score.
Furthermore, deﬁnition of ADRs and ADEs varies between
studies.
According to the literature, a possible risk factor for
the occurrence of adverse reactions in the paediatric
population is the use of off-label and unlicensed used
drugs. Horen et al9 found a relative risk of 3.44 (95% CI
1.26 to 9.38), for an ADR caused by off-label prescribed
drugs in the out-patient clinic. Turner et al10 found that
the use of unlicensed and off-label used drugs was asso-
ciated with a 50% increase in ADRs in 936 paediatric
inpatients. In our study no such relationship was found.
An explanation for this could be the difference in popu-
lation (acute admissions) and the relatively low number
of ADRs as a reason for admission. In order to prove a
relation a larger number of patients or a case–control
design is necessary.
A study in the Dutch adult population found that
46.6% of ADEs were possibly preventable.5 Studies in
the paediatric population found similar percentages of
33–51.3.20–22 In our study only 10% of ADRs was avoid-
able (table 2). Our data were based primarily on
medical charts, possibly leading to missed signals that
pointed towards an avoidable cause of the ADR. This
may also explain our percentage of avoidable cases
being lower than in the other studies. For example,
Gallagher et al collected extra data through interviews
with parents to get a better insight into medication use
of children before admission.
Certain limitations to this study must be acknowl-
edged. First, the trigger list might be incomplete. The
trigger list has been based on experience in adult medi-
cine concerning ADRs and was modiﬁed by expert
experience to suit the paediatric setting. Second, the
number of patients in this study was limited. This could
have inﬂuenced the lack of signiﬁcant results on the
relation between ADRs and the licensing state of admi-
nistered medication. Furthermore, the duration of
drug use before admission and time of last dose prior
to admission were not recorded. This may have been
relevant for the likelihood of an ADR. Finally the
results cannot be extrapolated to all other settings
because the study was carried out at an academic insti-
tution. In conclusion, this study shows a relatively low
percentage of ADR-related admissions in paediatric
patients, with the exception of patients exposed to
cancer chemotherapy.
CONCLUSION
In conclusion this study shows that ADRs occur more fre-
quently in the paediatric population compared to adults,
and more frequently in patients exposed to cancer
chemotherapy. The ADRs that occurred were caused by
vaccinations, anti-infectives for systemic use, antineoplas-
tic and immunomodulating drugs and by medication for
the nervous system. All ADRs in the paediatric wards and
ICU as well as the oncology ward were relatively mild,
none of the patients suffered permanent harm. No rela-
tion was found between the use of unlicensed and off-
label use of drugs and the incidence of ADRs.
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